Harry Kleanthous
Corporate Officer/Principal bij SK BIOSCIENCE CO.,LTD.
Profiel
Harry Kleanthous is currently working as Vice President-Research at Acambis Plc and EVP-Vaccine Research & Development Strategy at SK bioscience Co., Ltd.
He holds a doctorate degree from the University of London.
Actieve functies van Harry Kleanthous
Bedrijven | Functie | Begin |
---|---|---|
SK BIOSCIENCE CO.,LTD. | Corporate Officer/Principal | 21-10-2022 |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
Opleiding van Harry Kleanthous
University of London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SK BIOSCIENCE CO.,LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |